Skip to main content
PMC home page
Journal of Clinical Microbiology logoLink to Journal of Clinical Microbiology
. 1991 Feb;29(2):398–400. doi: 10.1128/jcm.29.2.398-400.1991

Pseudoresistance of Pseudomonas aeruginosa resulting from degradation of imipenem in an automated susceptibility testing system with predried panels.

R L White 1, M B Kays 1, L V Friedrich 1, E W Brown 1, J R Koonce 1
PMCID: PMC269776  PMID: 1822083

Abstract

During the use of a single lot of custom breakpoint panels (Sensititre; Radiometer America Inc., Westlake, Ohio), imipenem susceptibility declined from 70 to 44% for clinical isolates of Pseudomonas aeruginosa. With a new lot, susceptibility increased to 73%. Subsequent evaluations with P. aeruginosa ATCC 27853 revealed a similar susceptibility pattern and an increase in the MIC of imipenem when determined in panels with increasing ages. Imipenem concentrations were determined by high-performance liquid chromatography by using 11 different lots of MIC and breakpoint panels (139 to 893 days of age). The amount of imipenem remaining declined from 94.4 to 13.8% (r = 0.9225) over the age range of the panels. These data suggest that imipenem in Sensititre MIC and breakpoint panels degrades over time and that the decrease in imipenem may be largely responsible for the decline in P. aeruginosa susceptibility.

Full text

PDF
398

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baron E. J., Hindler J. A. Bioactivity of imipenem as a function of medium, time, and temperature. Antimicrob Agents Chemother. 1984 Jun;25(6):781–782. doi: 10.1128/aac.25.6.781. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Barry A. L., Jones R. N., Thornsberry C., Ayers L. W., Kundargi R. Imipenem (N-formimidoyl thienamycin): in vitro antimicrobial activity and beta-lactamase stability. Diagn Microbiol Infect Dis. 1985 Mar;3(2):93–104. doi: 10.1016/0732-8893(85)90017-3. [DOI] [PubMed] [Google Scholar]
  3. Cohn D. L., Reimer L. G., Reller L. B. Comparative in-vitro activity of MK0787 (N-formimidoyl thienamycin) against 540 blood culture isolates. J Antimicrob Chemother. 1982 Mar;9(3):183–194. doi: 10.1093/jac/9.3.183. [DOI] [PubMed] [Google Scholar]
  4. Edwards J. R., Turner P. J., Wannop C., Withnell E. S., Grindey A. J., Nairn K. In vitro antibacterial activity of SM-7338, a carbapenem antibiotic with stability to dehydropeptidase I. Antimicrob Agents Chemother. 1989 Feb;33(2):215–222. doi: 10.1128/aac.33.2.215. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Kropp H., Sundelof J. G., Kahan J. S., Kahan F. M., Birnbaum J. MK0787 (N-formimidoyl thienamycin): evaluation of in vitro and in vivo activities. Antimicrob Agents Chemother. 1980 Jun;17(6):993–1000. doi: 10.1128/aac.17.6.993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Lynch M. J., Drusano G. L., Mobley H. L. Emergence of resistance to imipenem in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1987 Dec;31(12):1892–1896. doi: 10.1128/aac.31.12.1892. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Nickolai D. J., Lammel C. J., Byford B. A., Morris J. H., Kaplan E. B., Hadley W. K., Brooks G. F. Effects of storage temperature and pH on the stability of eleven beta-lactam antibiotics in MIC trays. J Clin Microbiol. 1985 Mar;21(3):366–370. doi: 10.1128/jcm.21.3.366-370.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Ogle J. W., Reller L. B., Vasil M. L. Development of resistance in Pseudomonas aeruginosa to imipenem, norfloxacin, and ciprofloxacin during therapy: proof provided by typing with a DNA probe. J Infect Dis. 1988 Apr;157(4):743–748. doi: 10.1093/infdis/157.4.743. [DOI] [PubMed] [Google Scholar]
  9. Quinn J. P., Dudek E. J., DiVincenzo C. A., Lucks D. A., Lerner S. A. Emergence of resistance to imipenem during therapy for Pseudomonas aeruginosa infections. J Infect Dis. 1986 Aug;154(2):289–294. doi: 10.1093/infdis/154.2.289. [DOI] [PubMed] [Google Scholar]
  10. Rapp R. P., Young B., Bertch K., Tibbs P., Foster T. S. Clinical outcome of nosocomial pneumonia following imipenem/cilastatin therapy. Drug Intell Clin Pharm. 1987 Mar;21(3):272–276. doi: 10.1177/106002808702100308. [DOI] [PubMed] [Google Scholar]
  11. Staneck J. L. Imipenem susceptibility testing with a commercially prepared dry-format microdilution tray. J Clin Microbiol. 1986 Jun;23(6):1134–1135. doi: 10.1128/jcm.23.6.1134-1135.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Swanson D. J., DeAngelis C., Smith I. L., Schentag J. J. Degradation kinetics of imipenem in normal saline and in human serum. Antimicrob Agents Chemother. 1986 May;29(5):936–937. doi: 10.1128/aac.29.5.936. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Tally F. P., Jacobus N. V., Gorbach S. L. In vitro activity of N-formimidoyl thienamycin (MK0787). Antimicrob Agents Chemother. 1980 Oct;18(4):642–644. doi: 10.1128/aac.18.4.642. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Trumbore D., Pontzer R., Levison M. E., Kaye D., Cynamon M., Liu C., Hinthorn D. R., Tan J. S., File T. M. Multicenter study of the clinical efficacy of imipenem/cilastatin for treatment of serious infections. Rev Infect Dis. 1985 Jul-Aug;7 (Suppl 3):S476–S481. doi: 10.1093/clinids/7.supplement_3.s476. [DOI] [PubMed] [Google Scholar]
  15. Turgeon P. L., Desrochers C. Stability of imipenem in Mueller-Hinton agar stored at 4 degrees C. Antimicrob Agents Chemother. 1985 Nov;28(5):711–712. doi: 10.1128/aac.28.5.711. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Winston D. J., McGrattan M. A., Busuttil R. W. Imipenem therapy of Pseudomonas aeruginosa and other serious bacterial infections. Antimicrob Agents Chemother. 1984 Nov;26(5):673–677. doi: 10.1128/aac.26.5.673. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Zajac B. A., Fisher M. A., Gibson G. A., MacGregor R. R. Safety and efficacy of high-dose treatment with imipenem-cilastatin in seriously ill patients. Antimicrob Agents Chemother. 1985 May;27(5):745–748. doi: 10.1128/aac.27.5.745. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Microbiology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES